Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


18 criteria for choosing GSK's Cervarix

This article was originally published in Scrip

Executive Summary

For those wondering how the department of health chose between GlaxoSmithKline's Cervarix and Sanofi Pasteur MSD's Gardasil for the UK's cervical cancer vaccine campaign (Scrip No 3373, p 1), health minister Dawn Primarolo has listed in a recent parliamentary answer the 18 criteria that were used. As well as the obvious clinical and cost reasons, the criteria include pallet configuration, the robustness of manufacturing contingency arrangements, the risk of wastage if subjected to temperatures above 8°C, and the closeness of delivery schedules to requirements.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts